IDEAS home Printed from https://ideas.repec.org/a/sae/medema/v22y2002i5p417-430.html

Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment

Author

Listed:
  • Wolfgang C. Winkelmayer

    (Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts)

  • Milton C. Weinstein

    (Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts)

  • Murray A. Mittleman

    (Department of Epidemiology, Harvard School of Public Health, and the Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts)

  • Robert J. Glynn

    (Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts)

  • Joseph S. Pliskin

    (Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, Department of Health Policy and Management, Ben-Gurion University of the Negev, Beer Sheba, Israel)

Abstract

This article synthesizes the evidence on the cost-effectiveness of renal replacement therapy and discusses the findings in light of the frequent practice of using the cost-effectiveness of hemodialysis as a benchmark of societal willingness to pay. The authors conducted a meta-analytic review of the medical and economic literature for economic evaluations of hemodialysis, peritoneal dialysis, and kidney transplantation. Cost-effectiveness ratios were translated into 2000 U.S. dollars per life-year (LY) saved. Thirteen studies published between 1968 and 1998 provided such information. The cost-effectiveness of center hemodialysis remained within a narrow range of $55,000 to $80,000/LY in most studies despite considerable variation in methodology and imputed costs. The cost-effectiveness of home hemodialysis was found to be between $33,000 and $50,000/LY. Kidney transplantation, however, has become more cost-effective over time, approaching $10,000/LY. Estimates of the cost per life-year gained from hemodialysis have been remarkably stable over the past 3 decades, after adjusting for price levels. Uses of the cost-effectiveness ratio of $55,000/LY for center hemodialysis as a lower boundary of society’s willingness to pay for an additional life-year can be supported under certain assumptions.

Suggested Citation

  • Wolfgang C. Winkelmayer & Milton C. Weinstein & Murray A. Mittleman & Robert J. Glynn & Joseph S. Pliskin, 2002. "Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment," Medical Decision Making, , vol. 22(5), pages 417-430, October.
    • Handle: RePEc:sae:medema:v:22:y:2002:i:5:p:417-430
    DOI: 10.1177/027298902236927
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/027298902236927
    Download Restriction: no
    File URL: https://libkey.io/10.1177/027298902236927?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
    2. Drummond, Michael & Torrance, George & Mason, James, 1993. "Cost-effectiveness league tables: More harm than good?," Social Science & Medicine, Elsevier, vol. 37(1), pages 33-40, July.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jan Jürgensen & Robert Ikenberg & Roger-Axel Greiner & Volker Hösel, 2015. "Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 377-390, May.
    2. Jennie McKenney & Anders Chen & Karen W Hoover & Jane Kelly & David Dowdy & Parastu Sharifi & Patrick S Sullivan & Eli S Rosenberg, 2017. "Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men," PLOS ONE, Public Library of Science, vol. 12(6), pages 1-13, June.
    3. Andrea C Villanti & Yiding Jiang & David B Abrams & Bruce S Pyenson, 2013. "A Cost-Utility Analysis of Lung Cancer Screening and the Additional Benefits of Incorporating Smoking Cessation Interventions," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-11, August.
    4. Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
    5. Amitabh Chandra & Anupam B. Jena & Jonathan S. Skinner, 2011. "The Pragmatist's Guide to Comparative Effectiveness Research," Journal of Economic Perspectives, American Economic Association, vol. 25(2), pages 27-46, Spring.
    6. Murat Kurt & Mark S. Roberts & Andrew J. Schaefer & M. Utku Ünver, 2011. "Valuing Prearranged Paired Kidney Exchanges: A Stochastic Game Approach," Boston College Working Papers in Economics 785, Boston College Department of Economics, revised 14 Oct 2011.
    7. Mohsen Yaghoubi & Sonya Cressman & Louisa Edwards & Steven Shechter & Mary M. Doyle-Waters & Paul Keown & Ruth Sapir-Pichhadze & Stirling Bryan, 2023. "A Systematic Review of Kidney Transplantation Decision Modelling Studies," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 39-51, January.
    8. repec:max:cprpbr:30 is not listed on IDEAS
    9. Gafni, Amiram & Birch, Stephen, 2006. "Incremental cost-effectiveness ratios (ICERs): The silence of the lambda," Social Science & Medicine, Elsevier, vol. 62(9), pages 2091-2100, May.
    10. Jan Jürgensen & Wolfgang Arns & Bastian Haß, 2010. "Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 15-25, February.
    11. Ewa Orlewska & Piotr Mierzejewski, 2003. "Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(4), pages 296-303, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
    2. Tappenden, P & Brazier, J & Ratcliffe, J, 2006. "Does the National Institute for Health and Clinical Excellence take account of factors such as uncertainty and equity as well as incremental cost-effectiveness in commissioning health care services? A," MPRA Paper 29772, University Library of Munich, Germany.
    3. Rutten, Frans, 1996. "Economic evaluation and health care decision-making," Health Policy, Elsevier, vol. 36(3), pages 215-229, June.
    4. Coast, Joanna, 2018. "A history that goes hand in hand: Reflections on the development of health economics and the role played by Social Science & Medicine, 1967–2017," Social Science & Medicine, Elsevier, vol. 196(C), pages 227-232.
    5. Braden Manns & David Meltzer & Ken Taub & Cam Donaldson, 2003. "Illustrating the impact of including future costs in economic evaluations: an application to end‐stage renal disease care," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 949-958, November.
    6. Joseph Menzin & Lisa Lines & Daniel Weiner & Peter Neumann & Christine Nichols & Lauren Rodriguez & Irene Agodoa & Tracy Mayne, 2011. "A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease," PharmacoEconomics, Springer, vol. 29(10), pages 839-861, October.
    7. Cookson, Richard & Hutton, John, 2003. "Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective," Health Policy, Elsevier, vol. 63(2), pages 167-178, February.
    8. Sergio Iannazzo & Michela Carsi & Silvia Chiroli, 2012. "A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries," Applied Health Economics and Health Policy, Springer, vol. 10(2), pages 127-138, March.
    9. Drummond, Michael & Mason, James & Torrance, George, 1995. "Cost-effectiveness league tables: think of the fans," Health Policy, Elsevier, vol. 31(3), pages 231-238, March.
    10. Tom Jefferson & Miranda Mugford & Alastair Gray & Vittorio Demicheli, 1996. "An exercise on the feasibility of carrying out secondary economic analyses," Health Economics, John Wiley & Sons, Ltd., vol. 5(2), pages 155-165, March.
    11. Debby Postulart & Eddy M.M. Adang, 2000. "Response Shift and Adaptation in Chronically III Patients," Medical Decision Making, , vol. 20(2), pages 186-193, April.
    12. Steef Redeker & Sohal Ismail & Hester V. Eeren & Emma K. Massey & Willem Weimar & Mark Oppe & Jan Busschbach, 2022. "A dynamic Markov model to assess the cost-effectiveness of the Kidney Team at Home intervention in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(4), pages 597-606, June.
    13. Mohsen Yaghoubi & Sonya Cressman & Louisa Edwards & Steven Shechter & Mary M. Doyle-Waters & Paul Keown & Ruth Sapir-Pichhadze & Stirling Bryan, 2023. "A Systematic Review of Kidney Transplantation Decision Modelling Studies," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 39-51, January.
    14. Sigrid M Mohnen & Manon J M van Oosten & Jeanine Los & Martijn J H Leegte & Kitty J Jager & Marc H Hemmelder & Susan J J Logtenberg & Vianda S Stel & Leona Hakkaart-van Roijen & G Ardine de Wit, 2019. "Healthcare costs of patients on different renal replacement modalities – Analysis of Dutch health insurance claims data," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-14, August.
    15. Alexander V van Schoonhoven & Judith J Gout-Zwart & Marijke J S de Vries & Antoinette D I van Asselt & Evgeni Dvortsin & Pepijn Vemer & Job F M van Boven & Maarten J Postma, 2019. "Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-22, September.
    16. Lindholm, Lars & Rosen, Mans & Emmelin, Maria, 1996. "An epidemiological approach towards measuring the trade-off between equity and efficiency in health policy," Health Policy, Elsevier, vol. 35(3), pages 205-216, March.
    17. James Mason & Mike Drummond, 1995. "The DH register of cost-effectiveness studies: a review of study content and quality," Working Papers 128chedp, Centre for Health Economics, University of York.
    18. Gijs Van de Wetering & Willem H. Woertman & Eddy M. M. Adang, 2012. "A model to correct for short‐run inefficiencies in economic evaluations in healthcare," Health Economics, John Wiley & Sons, Ltd., vol. 21(3), pages 270-281, March.
    19. Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills, 2009. "Cost Effectiveness in Low- and Middle-Income Countries," PharmacoEconomics, Springer, vol. 27(11), pages 903-917, November.
    20. Richard H. Chapman & Patricia W. Stone & Eileen A. Sandberg & Chaim Bell & Peter J. Neumann, 2000. "A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" Studies," Medical Decision Making, , vol. 20(4), pages 451-458, October.

    More about this item

    Keywords

    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:22:y:2002:i:5:p:417-430. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.